Header Logo

Connection

SUZANNE FUQUA to Drug Resistance, Neoplasm

Back to Details
This is a "connection" page, showing publications SUZANNE FUQUA has written about Drug Resistance, Neoplasm.
SUZANNE FUQUA
Connection Strength
2.972
Drug Resistance, Neoplasm
  1. ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges. Br J Cancer. 2022 02; 126(2):174-186.
    View in: PubMed
    Score: 0.521
  2. RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer. Br J Cancer. 2021 01; 124(1):191-206.
    View in: PubMed
    Score: 0.491
  3. Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor alpha and its phosphorylation at serine 305. Breast Cancer Res Treat. 2010 Jan; 119(1):71-85.
    View in: PubMed
    Score: 0.217
  4. Estrogen receptors in resistance to hormone therapy. Adv Exp Med Biol. 2007; 608:130-43.
    View in: PubMed
    Score: 0.187
  5. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer. Clin Cancer Res. 2004 Nov 15; 10(22):7490-9.
    View in: PubMed
    Score: 0.162
  6. PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 01; 23(10):1494-1510.
    View in: PubMed
    Score: 0.160
  7. Leptin Signaling Contributes to Aromatase Inhibitor Resistant Breast Cancer Cell Growth and Activation of Macrophages. Biomolecules. 2020 04 03; 10(4).
    View in: PubMed
    Score: 0.117
  8. ESR1 mutations in breast cancer. Cancer. 2019 11 01; 125(21):3714-3728.
    View in: PubMed
    Score: 0.112
  9. Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. J Natl Cancer Inst. 1999 Mar 03; 91(5):453-9.
    View in: PubMed
    Score: 0.109
  10. Targeted therapy for breast cancer and molecular mechanisms of resistance to treatment. Curr Opin Pharmacol. 2016 12; 31:97-103.
    View in: PubMed
    Score: 0.093
  11. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERa-positive breast cancer. Breast Cancer Res Treat. 2015 Nov; 154(2):225-37.
    View in: PubMed
    Score: 0.086
  12. Targeting thyroid hormone receptor beta in triple-negative breast cancer. Breast Cancer Res Treat. 2015 Apr; 150(3):535-45.
    View in: PubMed
    Score: 0.083
  13. AR collaborates with ERa in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat. 2014 Oct; 147(3):473-85.
    View in: PubMed
    Score: 0.080
  14. Tamoxifen regulates cell fate through mitochondrial estrogen receptor beta in breast cancer. Oncogene. 2013 Jul 04; 32(27):3274-85.
    View in: PubMed
    Score: 0.069
  15. Dicer-mediated upregulation of BCRP confers tamoxifen resistance in human breast cancer cells. Clin Cancer Res. 2011 Oct 15; 17(20):6510-21.
    View in: PubMed
    Score: 0.065
  16. Loss of Rho GDIa and resistance to tamoxifen via effects on estrogen receptor a. J Natl Cancer Inst. 2011 Apr 06; 103(7):538-52.
    View in: PubMed
    Score: 0.063
  17. Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May; 121(1):1-11.
    View in: PubMed
    Score: 0.056
  18. Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway. Cancer Res. 2009 Jun 01; 69(11):4724-32.
    View in: PubMed
    Score: 0.055
  19. Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res. 2006 Jun 01; 66(11):5950-9.
    View in: PubMed
    Score: 0.045
  20. Metabolomic Rewiring Promotes Endocrine Therapy Resistance in Breast Cancer. Cancer Res. 2024 01 16; 84(2):291-304.
    View in: PubMed
    Score: 0.038
  21. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003 Mar 05; 95(5):353-61.
    View in: PubMed
    Score: 0.036
  22. Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival. Oncogene. 2018 08; 37(33):4489-4504.
    View in: PubMed
    Score: 0.026
  23. Tamoxifen through GPER upregulates aromatase expression: a novel mechanism sustaining tamoxifen-resistant breast cancer cell growth. Breast Cancer Res Treat. 2014 Jul; 146(2):273-85.
    View in: PubMed
    Score: 0.020
  24. Leptin increases HER2 protein levels through a STAT3-mediated up-regulation of Hsp90 in breast cancer cells. Mol Oncol. 2013 Jun; 7(3):379-91.
    View in: PubMed
    Score: 0.018
  25. Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression. Oncogene. 2011 Sep 29; 30(39):4129-40.
    View in: PubMed
    Score: 0.016
  26. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res. 2011 Jan 15; 71(2):603-13.
    View in: PubMed
    Score: 0.015
  27. Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivity. Oncogene. 2010 Apr 22; 29(16):2404-14.
    View in: PubMed
    Score: 0.014
  28. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst. 2000 Dec 06; 92(23):1926-34.
    View in: PubMed
    Score: 0.008
  29. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res. 1997 Aug 15; 57(16):3486-93.
    View in: PubMed
    Score: 0.006
  30. Multiple splicing variants of the estrogen receptor are present in individual human breast tumors. J Steroid Biochem Mol Biol. 1996 Nov; 59(3-4):251-60.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.